COLUMBIA, Md., Sept. 10 — A top 5 bio-pharmaceutical company has licensed BioFortis’ Labmatrix(TM) software for use enterprise-wide, across multiple therapeutic areas within its global Translational Medicine organization, BioFortis officials announced today. This large biopharmaceutical company decided to adopt the Labmatrix technology after an extensive review process that included a pilot by end users and the research informatics division. The company expects full implementation of Labmatrix to have a rapid and profound effect on the productivity of its Translational Medicine efforts.

“Labmatrix is the only data management and exploration application on the market that is built from the ground up to support translational medicine and biomarker discovery,” said Jian Wang, BioFortis President and CEO. “There is a growing need in the biotechnology and pharmaceutical industry for robust informatics systems in the translational medicine space. This agreement demonstrates BioFortis’ leadership position in fulfilling such needs,” Dr. Wang concluded.

Labmatrix, an enterprise translational research information management software product, will be used to support Translational Medicine initiatives associated with research programs, clinical trials, and longitudinal clinical studies conducted with external collaborators.

About BioFortis

BioFortis is a privately-held company focused on providing biomedical research software and services to the life sciences sector, including government and academic research institutes and the biopharmaceutical industry. BioFortis’ flagship product Labmatrix(TM) supports translational medicine initiatives with applications in clinical research, biobanking and biomarker discovery. Labmatrix enables transparent data management, integration, collaboration and compliance to privacy regulations.